332 related items for PubMed ID: 25938778
1. Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial.
Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F, Jin X, Gao J, Li J, Fang H, Liu G, Shi L, Du J, Li Y, Yan M, Wen Y, Yang W.
PLoS One; 2015; 10(5):e0126027. PubMed ID: 25938778
[Abstract] [Full Text] [Related]
2. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease.
Yang X, Zhang B, Lu X, Yan M, Wen Y, Zhao T, Li P.
BMC Complement Altern Med; 2016 Jul 26; 16():246. PubMed ID: 27460780
[Abstract] [Full Text] [Related]
3. Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial.
Yan M, Wen Y, Yang L, Wu X, Lu X, Zhang B, Huang W, Li P.
Trials; 2016 May 23; 17(1):259. PubMed ID: 27216240
[Abstract] [Full Text] [Related]
4. Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial.
Jin D, Huang WJ, Meng X, Yang F, Bao Q, Zhang MZ, Yang YN, Ni Q, Lian FM, Tong XL.
Trials; 2019 Dec 21; 20(1):756. PubMed ID: 31864393
[Abstract] [Full Text] [Related]
5. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
Zhao XM, Zhang Y, He XH, Chen HD, Wang ZF, Guo J, Wang XM, Gao ZZ, Wang JP, Liu W, Zhao LH, Tong XL.
Trials; 2018 Mar 27; 19(1):200. PubMed ID: 29587863
[Abstract] [Full Text] [Related]
6. Effects of traditional Chinese herbal medicine in patients with diabetic kidney disease: study protocol for a randomized controlled trial.
Wang M, Wang Z, Zhou J, Sun W, Wang Y, Han M, Yang H, Liu WJ, Wang Y.
Trials; 2018 Jul 17; 19(1):389. PubMed ID: 30016983
[Abstract] [Full Text] [Related]
7. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E, Lankarani KB.
Am J Kidney Dis; 2012 Dec 17; 60(6):896-903. PubMed ID: 22770926
[Abstract] [Full Text] [Related]
8. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
Wu R, Wei F, Qu L, Bai L, Li J, Li F, Yan W, Wang Q, Wei J.
Trials; 2020 Nov 23; 21(1):951. PubMed ID: 33228726
[Abstract] [Full Text] [Related]
9. Oral Chinese Herbal Medicine plus usual care for diabetic kidney disease: study protocol for a randomized, double-blind, placebo-controlled pilot trial.
Liu M, Di YM, Zhang L, Yang L, Zhang L, Chen J, Wang R, Xie X, Lan F, Xie L, Huang J, Zhang AL, Xue CC, Liu X.
Front Endocrinol (Lausanne); 2024 Nov 23; 15():1334609. PubMed ID: 38390199
[Abstract] [Full Text] [Related]
10. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM, Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group.
JAMA; 2015 Sep 01; 314(9):884-94. PubMed ID: 26325557
[Abstract] [Full Text] [Related]
11. 'Huang Qi Elixir' for proteinuria in patients with diabetic nephropathy: a study protocol for a randomized controlled pilot trial.
Tu X, Liu F, Jordan JB, Ye XF, Fu P, Wang F, Zhong S.
Trials; 2013 Jul 18; 14():223. PubMed ID: 23866835
[Abstract] [Full Text] [Related]
12. Prostaglandin E1 for preventing the progression of diabetic kidney disease.
Wang H, Deng JL, Yue J, Li J, Hou YB.
Cochrane Database Syst Rev; 2010 May 12; (5):CD006872. PubMed ID: 20464745
[Abstract] [Full Text] [Related]
13. The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
Wang H, Mu W, Zhai J, Xing D, Miao S, Wang J, Deng Y, Wang N, Chen H, Yang H, He X, Shang H.
Trials; 2013 Jun 05; 14():165. PubMed ID: 23738508
[Abstract] [Full Text] [Related]
14. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis.
Cai J, Huang X, Zheng Z, Lin Q, Peng M, Shen D.
Nephrol Dial Transplant; 2018 Nov 01; 33(11):1968-1976. PubMed ID: 29579289
[Abstract] [Full Text] [Related]
15. A randomized controlled clinical trial study protocol of Liuwei Dihuang pills in the adjuvant treatment of diabetic kidney disease.
Liao T, Zhao K, Huang Q, Tang S, Chen K, Xie C, Zhang C, Gan W.
Medicine (Baltimore); 2020 Jul 31; 99(31):e21137. PubMed ID: 32756091
[Abstract] [Full Text] [Related]
16. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
Knoll GA, Fergusson D, Chassé M, Hebert P, Wells G, Tibbles LA, Treleaven D, Holland D, White C, Muirhead N, Cantarovich M, Paquet M, Kiberd B, Gourishankar S, Shapiro J, Prasad R, Cole E, Pilmore H, Cronin V, Hogan D, Ramsay T, Gill J.
Lancet Diabetes Endocrinol; 2016 Apr 31; 4(4):318-26. PubMed ID: 26608067
[Abstract] [Full Text] [Related]
17. Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Zhang L, Li P, Xing CY, Zhao JY, He YN, Wang JQ, Wu XF, Liu ZS, Zhang AP, Lin HL, Ding XQ, Yin AP, Yuan FH, Fu P, Hao L, Miao LN, Xie RJ, Wang R, Zhou CH, Guan GJ, Hu Z, Lin S, Chang M, Zhang M, He LQ, Mei CL, Wang L, Chen X.
Am J Kidney Dis; 2014 Jul 31; 64(1):57-65. PubMed ID: 24631042
[Abstract] [Full Text] [Related]
18. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernández Vega F, Tato A, Gutierrez E, PRONEDI Study Group.
Am J Kidney Dis; 2013 Feb 31; 61(2):211-8. PubMed ID: 22939518
[Abstract] [Full Text] [Related]
19. Tangshen formula attenuates diabetic renal injuries by upregulating autophagy via inhibition of PLZF expression.
Zhao H, Li X, Zhao T, Zhang H, Yan M, Dong X, Chen P, Ma L, Li P.
PLoS One; 2017 Feb 31; 12(2):e0171475. PubMed ID: 28182710
[Abstract] [Full Text] [Related]
20. Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial.
Chen Y, Deng Y, Ni Z, Chen N, Chen X, Shi W, Zhan Y, Yuan F, Deng W, Zhong Y.
Am J Kidney Dis; 2013 Dec 31; 62(6):1068-76. PubMed ID: 23810688
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
